1
|
Treatment effects on event-related EEG potentials and oscillations in Alzheimer's disease. Int J Psychophysiol 2022; 177:179-201. [PMID: 35588964 DOI: 10.1016/j.ijpsycho.2022.05.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Revised: 05/11/2022] [Accepted: 05/12/2022] [Indexed: 11/23/2022]
Abstract
Alzheimer's disease dementia (ADD) is the most diffuse neurodegenerative disorder belonging to mild cognitive impairment (MCI) and dementia in old persons. This disease is provoked by an abnormal accumulation of amyloid-beta and tauopathy proteins in the brain. Very recently, the first disease-modifying drug has been licensed with reserve (i.e., Aducanumab). Therefore, there is a need to identify and use biomarkers probing the neurophysiological underpinnings of human cognitive functions to test the clinical efficacy of that drug. In this regard, event-related electroencephalographic potentials (ERPs) and oscillations (EROs) are promising candidates. Here, an Expert Panel from the Electrophysiology Professional Interest Area of the Alzheimer's Association and Global Brain Consortium reviewed the field literature on the effects of the most used symptomatic drug against ADD (i.e., Acetylcholinesterase inhibitors) on ERPs and EROs in ADD patients with MCI and dementia at the group level. The most convincing results were found in ADD patients. In those patients, Acetylcholinesterase inhibitors partially normalized ERP P300 peak latency and amplitude in oddball paradigms using visual stimuli. In these same paradigms, those drugs partially normalize ERO phase-locking at the theta band (4-7 Hz) and spectral coherence between electrode pairs at the gamma (around 40 Hz) band. These results are of great interest and may motivate multicentric, double-blind, randomized, and placebo-controlled clinical trials in MCI and ADD patients for final cross-validation.
Collapse
|
2
|
Li W, Kutas M, Gray JA, Hagerman RH, Olichney JM. The Role of Glutamate in Language and Language Disorders - Evidence from ERP and Pharmacologic Studies. Neurosci Biobehav Rev 2020; 119:217-241. [PMID: 33039453 DOI: 10.1016/j.neubiorev.2020.09.023] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2020] [Revised: 08/10/2020] [Accepted: 09/21/2020] [Indexed: 12/31/2022]
Abstract
Current models of language processing do not address mechanisms at the neurotransmitter level, nor how pharmacologic agents may improve language function(s) in seemingly disparate disorders. L-Glutamate, the primary excitatory neurotransmitter in the human brain, is extensively involved in various higher cortical functions. We postulate that the physiologic role of L-Glutamate neurotransmission extends to the regulation of language access, comprehension, and production, and that disorders in glutamatergic transmission and circuitry contribute to the pathogenesis of neurodegenerative diseases and sporadic-onset language disorders such as the aphasic stroke syndromes. We start with a review of basic science data pertaining to various glutamate receptors in the CNS and ways that they may influence the physiological processes of language access and comprehension. We then focus on the dysregulation of glutamate neurotransmission in three conditions in which language dysfunction is prominent: Alzheimer's Disease, Fragile X-associated Tremor/Ataxia Syndrome, and Aphasic Stroke Syndromes. Finally, we review the pharmacologic and electrophysiologic (event related brain potential or ERP) data pertaining to the role glutamate neurotransmission plays in language processing and disorders.
Collapse
Affiliation(s)
- Wentao Li
- Department of Neurology, University of California, Davis, 4860 Y Street, Suite 3700, Sacramento, CA, 95817, USA.
| | - Marta Kutas
- Department of Cognitive Science, University of California, San Diego, 9500 Gilman Drive #0515, La Jolla, CA, 92093, USA; Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.
| | - John A Gray
- Department of Neurology, University of California, Davis, 4860 Y Street, Suite 3700, Sacramento, CA, 95817, USA; Center for Neuroscience, University of California, Davis, 1544 Newton Court, Davis, CA, 95618, USA.
| | - Randi H Hagerman
- MIND Institute, University of California, Davis, 2825 50th Street, Sacramento, CA, 95817, USA.
| | - John M Olichney
- Department of Neurology, University of California, Davis, 4860 Y Street, Suite 3700, Sacramento, CA, 95817, USA; Center for Mind and Brain, University of California, Davis, 267 Cousteau Place, Davis, CA, 95618, USA.
| |
Collapse
|
3
|
Barbancho MA, Berthier ML, Navas-Sánchez P, Dávila G, Green-Heredia C, García-Alberca JM, Ruiz-Cruces R, López-González MV, Dawid-Milner MS, Pulvermüller F, Lara JP. Bilateral brain reorganization with memantine and constraint-induced aphasia therapy in chronic post-stroke aphasia: An ERP study. BRAIN AND LANGUAGE 2015; 145-146:1-10. [PMID: 25932618 DOI: 10.1016/j.bandl.2015.04.003] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/17/2014] [Revised: 02/06/2015] [Accepted: 04/11/2015] [Indexed: 06/04/2023]
Abstract
Changes in ERP (P100 and N400) and root mean square (RMS) were obtained during a silent reading task in 28 patients with chronic post-stroke aphasia in a randomized, double-blind, placebo-controlled trial of both memantine and constraint-induced aphasia therapy (CIAT). Participants received memantine/placebo alone (weeks 0-16), followed by drug treatment combined with CIAT (weeks 16-18), and then memantine/placebo alone (weeks 18-20). ERP/RMS values (week 16) decreased more in the memantine group than in the placebo group. During CIAT application (weeks 16-18), improvements in aphasia severity and ERP/RMS values were amplified by memantine and changes remained stable thereafter (weeks 18-20). Changes in ERP/RMS occurred in left and right hemispheres and correlated with gains in language performance. No changes in ERP/RMS were found in a healthy group in two separated evaluations. Our results show that aphasia recovery induced by both memantine alone and in combination with CIAT is indexed by bilateral cortical potentials.
Collapse
Affiliation(s)
- Miguel A Barbancho
- Universidad de Málaga, Andalucía TECH-IBIMA, Unidad de Neurofisiología Cognitiva, Centro de Investigaciones Médico-Sanitarias (CIMES), Marqués de Beccaria, 3, 29010 Málaga, Spain
| | - Marcelo L Berthier
- Universidad de Málaga, Andalucía TECH-IBIMA, Unidad de Afasia y Neurología Cognitiva, Centro de Investigaciones Médico-Sanitarias (CIMES) y Cátedra Fundación Morera y Vallejo de Afasia, Marqués de Beccaria, 3, 29010 Málaga, Spain
| | - Patricia Navas-Sánchez
- Universidad de Málaga, Andalucía TECH-IBIMA, Unidad de Neurofisiología Cognitiva, Centro de Investigaciones Médico-Sanitarias (CIMES), Marqués de Beccaria, 3, 29010 Málaga, Spain
| | - Guadalupe Dávila
- Universidad de Málaga, Andalucía TECH-IBIMA, Unidad de Afasia y Neurología Cognitiva, Centro de Investigaciones Médico-Sanitarias (CIMES) y Cátedra Fundación Morera y Vallejo de Afasia, Marqués de Beccaria, 3, 29010 Málaga, Spain
| | - Cristina Green-Heredia
- Departamento de Neurociencia, Hospital Quirón, Av. Imperio Argentina, 1, 29004 Málaga, Spain
| | | | - Rafael Ruiz-Cruces
- Universidad de Málaga, Andalucía TECH-IBIMA, Unidad de Neurofisiología Cognitiva, Centro de Investigaciones Médico-Sanitarias (CIMES), Marqués de Beccaria, 3, 29010 Málaga, Spain
| | - Manuel V López-González
- Universidad de Málaga, Andalucía TECH-IBIMA, Unidad de Neurofisiología Cognitiva, Centro de Investigaciones Médico-Sanitarias (CIMES), Marqués de Beccaria, 3, 29010 Málaga, Spain
| | - Marc S Dawid-Milner
- Universidad de Málaga, Andalucía TECH-IBIMA, Unidad de Neurofisiología Cognitiva, Centro de Investigaciones Médico-Sanitarias (CIMES), Marqués de Beccaria, 3, 29010 Málaga, Spain
| | - Friedemann Pulvermüller
- Brain Language Laboratory, Freie Universität Berlin, Germany; Medical Research Council, Cognition and Brain Sciences Unit, Cambridge, United Kingdom
| | - J Pablo Lara
- Universidad de Málaga, Andalucía TECH-IBIMA, Unidad de Neurofisiología Cognitiva, Centro de Investigaciones Médico-Sanitarias (CIMES), Marqués de Beccaria, 3, 29010 Málaga, Spain.
| |
Collapse
|
4
|
Kimiskidis VK, Papaliagkas VT. Event-related potentials for the diagnosis of mild cognitive impairment and Alzheimer's disease. ACTA ACUST UNITED AC 2011; 6:15-26. [PMID: 23480617 DOI: 10.1517/17530059.2012.634795] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Alzheimer's disease (AD) and the nosological entity of mild cognitive impairment (MCI) constitute a major public health concern. The diagnostic approach and therapeutic management of these disorders may be significantly improved by recent advances in the field of event-related potentials (ERPs). AREAS COVERED The authors performed a PubMed search in order to identify full-length, original research articles on the experimental and clinical application of ERPs in AD and MCI. The major part of the retrieved articles concerns the application of auditory and, to a lesser extent, visual ERPs for the early diagnosis of AD and MCI. Particular emphasis was placed on the role of ERPs in identifying the subgroup of MCI patients who will subsequently convert to AD. Other areas covered include the contribution of ERPs in the differential diagnosis of dementia types, the utility of ERPs for monitoring pharmacological treatment in AD and the correlation between ERPs and the results of neuropsychological testing. EXPERT OPINION The reviewed evidence suggests that ERPs hold promise as an electrophysiological tool for the early and accurate diagnosis of AD and MCI. However, certain methodological issues need to be resolved before ERPs enter the arena of clinical practice.
Collapse
Affiliation(s)
- Vasilios K Kimiskidis
- Aristotle University of Thessaloniki, Department of Neurology III, George Papanicolaou Hospital , 57010 Exokhi, Thessaloniki , Greece +302313307333, +30 2310 99 23 59 ; +2313307331 ;
| | | |
Collapse
|
5
|
Jiraskova N, Kuba M, Kremlacek J, Rozsival P. Normal sensory and absent cognitive electrophysiological responses in functional visual loss following chemical eye burn. Doc Ophthalmol 2011; 123:51-7. [PMID: 21647683 DOI: 10.1007/s10633-011-9275-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2011] [Accepted: 05/10/2011] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To present a unique case of a 34-year-old patient with unilateral functional visual loss after chemical burn with normal visual evoked potentials (VEPs) and absent cognitive response (P300 wave). METHODS Visual functions, complete ophthalmic and neurologic examinations including computed tomography of the brain, electrophysiological testing of the visual pathway up to the cognitive brain cortex were evaluated. Data were collected prospectively during 1-year follow-up and compared with data from published case series and a literature review. RESULTS No abnormalities were found that could account for such a rapid monocular loss of vision with exception of absence of the P300 wave in the affected eye during cognitive tasks. Vision slowly improved during 1 year without any treatment. CONCLUSIONS Functional vision loss is a diagnosis of exclusion. In the event of reduced vision in the context of a normal ocular health examination, all other pathology must be ruled out before the diagnosis of functional visual loss is established. Complex visual electrophysiological testing is the preferred tool for objective examination of such disorders.
Collapse
Affiliation(s)
- Nada Jiraskova
- Department of Ophthalmology, Charles University in Prague, Hradec Kralove, Czech Republic.
| | | | | | | |
Collapse
|
6
|
Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP/PS1 mouse model of Alzheimer’s disease. Neuropharmacology 2011; 60:930-6. [DOI: 10.1016/j.neuropharm.2011.01.035] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2010] [Revised: 01/14/2011] [Accepted: 01/20/2011] [Indexed: 11/22/2022]
|
7
|
Herrmann N, Li A, Lanctôt K. Memantine in dementia: a review of the current evidence. Expert Opin Pharmacother 2011; 12:787-800. [DOI: 10.1517/14656566.2011.558006] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|